Menu
US
leveraging-cld1920x640
Whitepaper

Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications

Using biologically sourced material for biotherapeutics has achieved significant success in recent years, with transformative innovations throughout the entire cell line development (CLD) process. Automation, clone selection, scalability, and digitization have all contributed to increased agility, precision, and throughput while meeting regulatory compliance requirements.

Explore this whitepaper detailing what the cell line development challenges are and how they can be addressed with advanced technologies. Covering areas such as:

  • How to prevent clone instability
  • Achieving acceptable protein expression
  • Allowing for non-fragmented, multi-copy gene cassette integration

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications

Download Whitepaper